



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 4946

**Title:** ERDHEIM CHESTER - a rare syndrome with unique endoscopic features.

**Reviewer code:** 00239992

**Science editor:** Zhai, Huan-Huan

**Date sent for review:** 2013-08-05 19:08

**Date reviewed:** 2013-08-30 00:26

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Dear Editor, thank you for giving me the opportunity to review this very interesting case report on a rare disease where many new findings have been made lately. I have nevertheless a few comments: -the manuscript should be carefully re-read by English native speaker: there are many mistakes (such as Langerhans (and not langerhance), Erdheim-Chester disease is the proper term, biopsy-proven (instead of proved)....). Erdheim-Chester disease can also be replaced by ECD as well. - I think the exact number of case reports found in the medical literature should be more clearly stated by the authors (instead of saying "few reports"). - The iconography is very impressive - The bibliography should be completed by the Blood 2011 series on 53 patients (Arnaud et al.) - Can the authors comment on the choice of treatment by vinblastine + prednisone as it is not at all classical regimen in ECD (but is classical in case of Langerhans cell histiocytosis). Why didn't they consider interferon alpha therapy or alternative therapies? - Authors should as well comment if possible on the evolution under treatment: was the endoscopy controlled under treatment?